Rhythm CEO Kei­th Gottes­di­ener hits the ex­it; Take­da sets up an AI dis­cov­ery pro­gram at MIT

→ Rhythm Phar­ma­ceu­ti­cals $RYTM CEO Kei­th Gottes­di­ener is plan­ning to stay at the helm un­til the biotech com­pletes its new drug ap­pli­ca­tion, and then head out. He says it’s the right time to hand over the reins and the com­pa­ny plans to or­ga­nize a search for his re­place­ment. His last task should be done by the end of Q1. “For the more than eight years that I have been CEO, it has been an hon­or to lead the tal­ent­ed Rhythm team, and I am im­mense­ly proud of our work to ad­vance set­melan­otide and bol­ster the un­der­stand­ing of rare ge­net­ic dis­or­ders of obe­si­ty,” said Gottes­di­ener in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER